EXICURE, INC.

XCUR Nasdaq CIK: 0001698530

Company Information

Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 2430 N. HALSTED ST., CHICAGO, IL, 60614
Mailing Address 2430 N. HALSTED ST., CHICAGO, IL, 60614
Phone 847-673-1707
Fiscal Year End 1231
EIN 815333008

Financial Overview

FY2025

$10.12M
Total Liabilities
$-0.79
EPS

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events March 27, 2026 View on SEC
10-K Annual financial report March 25, 2026 View on SEC
8-K Current report of material events March 25, 2026 View on SEC
4 Insider stock transaction report February 19, 2026 View on SEC
8-K Current report of material events February 17, 2026 View on SEC
8-K Current report of material events February 10, 2026 View on SEC
8-K Current report of material events January 22, 2026 View on SEC
4 Insider stock transaction report January 21, 2026 View on SEC
SCHEDULE 13D/A Beneficial ownership amendment January 21, 2026 View on SEC
4 Insider stock transaction report January 20, 2026 View on SEC

Annual Reports

10-K March 25, 2026
  • Transitioned from a biotech firm to a public shell entity seeking a reverse merger.
  • Successfully liquidated remaining intellectual property and lab equipment to generate liquidity.
View Analysis

Material Events

8-K Financial Distress March 25, 2026
High Impact
  • Active pursuit of a merger or acquisition as the company's sole path forward
  • Potential for a 'reverse merger' utilizing the company's existing public listing and patents
View Analysis
8-K Leadership Change February 17, 2026
High Impact
  • New leadership appointed through Innocircle Advisors Inc., suggesting specialized turnaround expertise.
  • Jung Soo Kim (new CEO & President) brings over 20 years in corporate strategy, M&A, and business reorganization.
View Analysis
8-K Leadership Change February 10, 2026
High Impact
  • New board members Jung Kyu Ham, Jung Soo Kim, and Gyeung Seog Cheon appointed to provide fresh perspectives and oversight.
  • Company stated resignations did not stem from disagreements, suggesting a planned transition.
View Analysis

Insider Trading

STRONG SELL 2 insiders 4 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2834)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.